Tumor microenvironment and immunotherapy for triple-negative breast cancer
Abstract Triple-negative breast cancer (TNBC) is a subtype of breast cancer known for its high aggressiveness and poor prognosis. Conventional treatment of TNBC is challenging due to its heterogeneity and lack of clear targets. Recent advancements in immunotherapy have shown promise in treating TNBC...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-12-01
|
| Series: | Biomarker Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40364-024-00714-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841559191995547648 |
|---|---|
| author | Zijie Guo Ziyu Zhu Xixi Lin Shenkangle Wang Yihong Wen Linbo Wang Lili Zhi Jichun Zhou |
| author_facet | Zijie Guo Ziyu Zhu Xixi Lin Shenkangle Wang Yihong Wen Linbo Wang Lili Zhi Jichun Zhou |
| author_sort | Zijie Guo |
| collection | DOAJ |
| description | Abstract Triple-negative breast cancer (TNBC) is a subtype of breast cancer known for its high aggressiveness and poor prognosis. Conventional treatment of TNBC is challenging due to its heterogeneity and lack of clear targets. Recent advancements in immunotherapy have shown promise in treating TNBC, with immune checkpoint therapy playing a significant role in comprehensive treatment plans. The tumor microenvironment (TME), comprising immune cells, stromal cells, and various cytokines, plays a crucial role in TNBC progression and response to immunotherapy. The high presence of tumor-infiltrating lymphocytes and immune checkpoint proteins in TNBC indicates the potential of immunotherapeutic strategies. However, the complexity of the TME, while offering therapeutic targets, requires further exploration of its multiple roles in immunotherapy. In this review, we discuss the interaction mechanism between TME and TNBC immunotherapy based on the characteristics and composition of TME, and elaborate on and analyze the effect of TME on immunotherapy, the potential of TME as an immune target, and the ability of TME as a biomarker. Understanding these dynamics will offer new insights for enhancing therapeutic approaches and investigating stratification and prognostic markers for TNBC patients. |
| format | Article |
| id | doaj-art-13532c7c76ee43f3a26b531f70318b92 |
| institution | Kabale University |
| issn | 2050-7771 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Biomarker Research |
| spelling | doaj-art-13532c7c76ee43f3a26b531f70318b922025-01-05T12:42:05ZengBMCBiomarker Research2050-77712024-12-0112111910.1186/s40364-024-00714-6Tumor microenvironment and immunotherapy for triple-negative breast cancerZijie Guo0Ziyu Zhu1Xixi Lin2Shenkangle Wang3Yihong Wen4Linbo Wang5Lili Zhi6Jichun Zhou7Department of Surgical Oncology, Affiliated Sir Run Shaw Hospital, Zhejiang University School of MedicineDepartment of Surgical Oncology, Affiliated Sir Run Shaw Hospital, Zhejiang University School of MedicineDepartment of Surgical Oncology, Affiliated Sir Run Shaw Hospital, Zhejiang University School of MedicineDepartment of Surgical Oncology, Affiliated Sir Run Shaw Hospital, Zhejiang University School of MedicineBiomedical Research Center, Key Laboratory of Biotherapy of Zhejiang ProvinceDepartment of Surgical Oncology, Affiliated Sir Run Shaw Hospital, Zhejiang University School of MedicineBiomedical Research Center, Key Laboratory of Biotherapy of Zhejiang ProvinceDepartment of Surgical Oncology, Affiliated Sir Run Shaw Hospital, Zhejiang University School of MedicineAbstract Triple-negative breast cancer (TNBC) is a subtype of breast cancer known for its high aggressiveness and poor prognosis. Conventional treatment of TNBC is challenging due to its heterogeneity and lack of clear targets. Recent advancements in immunotherapy have shown promise in treating TNBC, with immune checkpoint therapy playing a significant role in comprehensive treatment plans. The tumor microenvironment (TME), comprising immune cells, stromal cells, and various cytokines, plays a crucial role in TNBC progression and response to immunotherapy. The high presence of tumor-infiltrating lymphocytes and immune checkpoint proteins in TNBC indicates the potential of immunotherapeutic strategies. However, the complexity of the TME, while offering therapeutic targets, requires further exploration of its multiple roles in immunotherapy. In this review, we discuss the interaction mechanism between TME and TNBC immunotherapy based on the characteristics and composition of TME, and elaborate on and analyze the effect of TME on immunotherapy, the potential of TME as an immune target, and the ability of TME as a biomarker. Understanding these dynamics will offer new insights for enhancing therapeutic approaches and investigating stratification and prognostic markers for TNBC patients.https://doi.org/10.1186/s40364-024-00714-6Triple-negative breast cancer (TNBC)ImmunotherapyTumor microenvironment (TME)Immune checkpointCancer treatment protocolsBiomarkers |
| spellingShingle | Zijie Guo Ziyu Zhu Xixi Lin Shenkangle Wang Yihong Wen Linbo Wang Lili Zhi Jichun Zhou Tumor microenvironment and immunotherapy for triple-negative breast cancer Biomarker Research Triple-negative breast cancer (TNBC) Immunotherapy Tumor microenvironment (TME) Immune checkpoint Cancer treatment protocols Biomarkers |
| title | Tumor microenvironment and immunotherapy for triple-negative breast cancer |
| title_full | Tumor microenvironment and immunotherapy for triple-negative breast cancer |
| title_fullStr | Tumor microenvironment and immunotherapy for triple-negative breast cancer |
| title_full_unstemmed | Tumor microenvironment and immunotherapy for triple-negative breast cancer |
| title_short | Tumor microenvironment and immunotherapy for triple-negative breast cancer |
| title_sort | tumor microenvironment and immunotherapy for triple negative breast cancer |
| topic | Triple-negative breast cancer (TNBC) Immunotherapy Tumor microenvironment (TME) Immune checkpoint Cancer treatment protocols Biomarkers |
| url | https://doi.org/10.1186/s40364-024-00714-6 |
| work_keys_str_mv | AT zijieguo tumormicroenvironmentandimmunotherapyfortriplenegativebreastcancer AT ziyuzhu tumormicroenvironmentandimmunotherapyfortriplenegativebreastcancer AT xixilin tumormicroenvironmentandimmunotherapyfortriplenegativebreastcancer AT shenkanglewang tumormicroenvironmentandimmunotherapyfortriplenegativebreastcancer AT yihongwen tumormicroenvironmentandimmunotherapyfortriplenegativebreastcancer AT linbowang tumormicroenvironmentandimmunotherapyfortriplenegativebreastcancer AT lilizhi tumormicroenvironmentandimmunotherapyfortriplenegativebreastcancer AT jichunzhou tumormicroenvironmentandimmunotherapyfortriplenegativebreastcancer |